Myocardial improvement with human embryonic stem cell-derived cardiomyocytes enriched by p38MAPK inhibition.

@article{Yeghiazarians2012MyocardialIW,
  title={Myocardial improvement with human embryonic stem cell-derived cardiomyocytes enriched by p38MAPK inhibition.},
  author={Yerem Yeghiazarians and Meenakshi Gaur and Yan Zhang and Richard E. Sievers and Carissa Ritner and M Hanumantha Prasad and A. K. Boyle and Harold S Bernstein},
  journal={Cytotherapy},
  year={2012},
  volume={14 2},
  pages={
          223-31
        }
}
BACKGROUND AIMS We have shown previously that inhibition of the p38 mitogen-activated protein kinase (p38MAPK) directs the differentiation of human embryonic stem cell (hESC)-derived cardiomyocytes (hCM). We investigated the therapeutic benefits of intramyocardial injection of hCM differentiated from hESC by p38MAPK inhibition using closed-chest ultrasound-guided injection at a clinically relevant time post-myocardial infarction (MI) in a mouse model. METHODS MI was induced in mice and the… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

Similar Papers

Loading similar papers…